Table 2. Drug resistant mutations (DRM) identified in HAART-naïve newly diagnosed infected individuals in Banna, China.
| Category | DRM | Cases | Suspectivity | ||||||
| NRTI | 3TC | ABC | AZT | D4T | DDI | FTC | TDF | ||
| A62V | 1 | S | S | S | S | S | S | S | |
| T69N | 5 | S | S | S | S | PL | S | S | |
| T69S | 7 | S | S | S | S | S | S | S | |
| M184V | 1 | H | L | S | S | PL | H | S | |
| M184I | 1 | H | L | S | S | PL | H | S | |
| T215S | 1 | S | PL | L | L | PL | S | S | |
| T215A | 1 | S | PL | L | L | PL | S | S | |
| K219N | 1 | S | S | PL | PL | S | S | S | |
| NNRTI | EFV | ETR | NVP | RPV | |||||
| V90I | 17 | S | S | S | S | S | S | S | |
| A98G | 8 | PL | PL | IM | L | ||||
| L100V | 1 | IM | PL | IM | L | ||||
| K103N | 1 | H | S | H | S | ||||
| K103E | 1 | S | S | S | S | ||||
| V106I | 4 | S | S | S | S | ||||
| E138A | 13 | S | PL | S | L | ||||
| V179D | 17 | PL | PL | PL | PL | ||||
| V179T | 7 | PL | PL | PL | PL | ||||
| G190R | 1 | S | S | S | S | ||||
| H221Y | 1 | PL | PL | PL | PL | ||||
| PI Major | ATV/r | DRV/r | FPV/r | IDV/r | LPV/r | NFV | SQV/r | ||
| D30N | 1 | S | S | S | S | S | H | S | |
| M46I | 1 | PL | S | PL | PL | PL | L | S | |
| M46L | 2 | PL | S | PL | PL | PL | L | S | |
| PI minor * | |||||||||
| L10V | 8 | S | S | S | S | S | S | S | |
| L10I | 8 | S | S | S | S | S | S | S | |
| L10F | 1 | S | S | PL | PL | S | PL | S | |
| V11I | 2 | S | S | S | S | S | S | S | |
| K20I | 1 | S | S | S | S | S | PL | S | |
| L33I | 1 | S | S | S | S | S | S | S | |
| G48R | 1 | S | S | S | S | S | S | S | |
| Q58E | 3 | S | S | S | S | S | L | S | |
| A71T | 3 | S | S | S | S | S | S | S | |
| A71V | 6 | S | S | S | S | S | S | S | |
| T74S | 3 | S | S | S | S | S | L | S | |
| TOTAL 33 DRMs 130 (in 104/283 infectors, 36.7%) | |||||||||
Note: DRMs analyses were implemented based on HIVdb algorithm. Bold font indicated DRMs which were also included in CPR ver.6.0 (SDRM 2009). Italic font indicated DRMs not included in 2013 IAS-USA.
*L33F is polymorphic in 19 individuals infected with HIV-1 subtype CRF01_AE.
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; EFV, efavirenz; NVP, nevirapine; NFV, nelfinavir; ATV, Atazanavir; LPV/r, lopinavir and ritonavir; IDV, indinavir; S, susceptible; H, high-level resistance; I, intermediate resistance; L, low-level resistance; and PL, potential low-level resistance.